检索历史 清除

目的:分析扶元复衡汤联合培美曲塞化学治疗晚期肺癌对患者体力状态、肿瘤标志物及无进展生存期(PFS)的影响。方法:本研究为回顾性随机对照研究，选取2021年1月至2023年12月陕西中医药大学第二附属医院肿瘤乳腺外科收治的100例晚期肺癌患者，男58例，女42例，年龄(59.61±7.08)岁，年龄范围为25～79岁。用随机数表法将患者随机分为培美曲塞组与扶元复衡汤组，每组50例。比较两组患者的治疗效果、体力情况[卡诺夫斯凯计分(KPS)]，肿瘤标志物[糖类抗原125(CA125)、癌胚抗原]及不良反应发生情况；对患者进行为期1年的随访，比较两组患者PFS。结果:扶元复衡汤组疾病控制率[94.0%(47/50)]高于培美曲塞组[78.0%(39/50)]，差异有统计学意义( P<0.05)。治疗后，扶元复衡汤组KPS[(71.38±4.12)分]高于培美曲塞组[(67.35±4.38)分]，CA125[(42.17±4.59)U/ml]、癌胚抗原[(20.53±2.14)U/ml]低于培美曲塞组[(50.66±5.02)U/ml、(29.30±3.04)U/ml]，差异有统计学意义( P<0.05)。扶元复衡汤组患者不良反应发生率[10.0%(5/50)]低于培美曲塞组[26.0%(13/50)]，PFS[(7.85±1.23)个月]优于培美曲塞组[(6.07±0.95)个月]，差异有统计学意义( P<0.05)。 结论:在晚期肺癌培美曲塞化学治疗中增加扶元复衡汤治疗，对患者症状、体力状态、肿瘤标志物水平均有改善，同时可减少不良反应并延长患者PFS。

Objective:To analyze the effect of Fuyuan Fuheng Decoction combined with chemotherapy with pemetrexed on physical status, tumor markers, and progression-free survival (PFS) of patients with advanced lung cancer.Methods:This study was a retrospective randomized controlled study, a total of 100 patients with advanced lung cancer were selected from the department of Breast Cancer Surgery in Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2021 to December 2023, including 58 males and 42 females, aged (59.61±7.08) years old, the age ranging from 25 to 79 years old.The patients were randomly divided into pemetrexed group and Fuyuan Fuheng Decoction group, with 50 cases in each group.The two groups were compared in terms of therapeutic effects, physical condition [Kanofsky performance score (KPS)], tumor markers [carbohydrate antigen 125 (CA125) and carcinoembryonic antigen], and the incidence of adverse reactions.The patients were followed up for a year and the PFS of the two groups was compared.Results:The disease control rate of Fuyuan Fuheng Decoction group [94.0% (47/50)] was higher than that of pemetrexed group [78.0% (39/50)], and the difference was statistically significant ( P<0.05).After treatment, KPS of Fuyuan Fuheng Decoction group [(71.38±4.12) points] was higher than that of pemetrexed group [(67.35±4.38) points], the levels of CA125 [(42.17±4.59) U/ml] and carcinoembryonic antigen [(20.53±2.14) U/ml] were lower than those in pemetrexed group [(50.66±5.02) U/ml and (29.30±3.04) U/ml], and the differences were statistically significant ( P<0.05).The incidence of adverse reactions in Fuyuan Fuheng Decoction group [10.0% (5/50)] was lower than that in pemetrexed group [26.0% (13/50)], and PFS [(7.85±1.23) months] was better than that of pemetrexed group [(6.07±0.95) months], and the differences were statistically significant ( P<0.05). Conclusions:Applying Fuyuan Fuheng Decoction in pemetrexed chemotherapy for advanced lung cancer can improve the symptoms, physical status and tumor marker levels of patients, reduce adverse reactions and prolong PFS.